期刊文献+

乙型肝炎病毒核苷(酸)类似物耐药研究进展 被引量:6

Progress in hepatitis B virus resistance to nucleos(t)ide analogues
原文传递
导出
摘要 核苷(酸)类似物耐药问题是慢性乙型肝炎抗病毒治疗中的重要问题之一。随着核苷(酸)类似物耐药研究的不断进展,耐药检测新技术逐渐被研发,对病毒变异的机制了解更加精确且全面。核苷(酸)类似物新的可疑耐药位点不断被提出,但这些位点的临床意义尚待进一步明确。尤其是慢性乙型肝炎患者应用核苷(酸)类似物抗病毒治疗的过程即是病毒与机体相互作用的过程逐渐被认知,在此过程中病毒准种及全基因组序列存在动态演变。核苷(酸)类似物耐药仅为此相互作用过程的表现之一,应将核苷(酸)类似物耐药放在机体免疫与病毒相互作用的整体背景下进行研究。 Nucleos(t)ide analogues resistance is still one of the most important questions in management of patients with chronic hepatitis B. New techniques to detecting resistant mutations were developed, showing the resistance more precisely and comprehensively. New possible variants related to nucleos(t)ide analogues resistance were identified, but the clinical significance still need to be verified. The researches on nucleos(t)ide analogues resistance as one of the manifestations in dynamic interaction between HBV and host immunity during nucleos(t)ide analogues therapy were realized. And nucleos(t)ide analogues resistance in the background of virus-host interaction should be understanded.
作者 杨松 邢卉春 成军 Yang Song, Xing Huichun, Cheng Jun(Division 3 of Center of Hepatology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, Chin)
出处 《中华实验和临床感染病杂志(电子版)》 CAS 2018年第1期1-6,共6页 Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)
基金 北京市卫生系统高层次卫生技术人才队伍建设专项经费(No.2016-108) 北京市医院管理局扬帆计划项目(肝炎专业)(No.ZYLX201402) 登峰计划项目(肝病专业)(No.DFL20151701)
关键词 肝炎、乙型、慢性 肝炎病毒、乙型 耐药 Chronic hepatitis B Hepatitis B virus Resistance
  • 相关文献

参考文献2

二级参考文献81

  • 1闫杰,温少芳,王丹静,吴淑玲.乙型肝炎病毒耐药专家共识[J].中华实验和临床感染病杂志(电子版),2008,2(1):90-98. 被引量:40
  • 2Yeon JE,Yoo W,Hong SP.阿德福韦双酯治疗拉米夫定耐药的慢性乙肝患者时出现的耐药问题[J].中国处方药,2006(3):23-23. 被引量:81
  • 3European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol,2012,57 ( 1 ) : 167-185.
  • 4Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B : a 2012 update. Hepatol Int,2012,6(3) :531-561.
  • 5Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology, 2009,50 ( 3 ) : 661-662.
  • 6Yao GB, Zhu M, Cui ZY. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis,2009,10(2) :131-137.
  • 7Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis,2003,36(6) :687-696.
  • 8Papatheodoridis GV, Dimou E, Laras A, et al. Course of virologic breakthroughs under long-term lamivudine in I-IBeAg-negative precore mutant HBV liver disease. Hepatology ,2002,36( 1 ) :219-226.
  • 9Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology,2009,136 ( 2 ) :486-495.
  • 10Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med, 2007,357 ( 25 ) : 2576-2588.

共引文献16

同被引文献53

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部